Expanded Access to TICE BCG Substitute
FDA has approved an expanded access program authorizing ImmunityBio to provide recombinant BCG to urologists to address the TICE BCG shortage to treat bladder cancer. A company statement says the alternative BCG source was developed by the Serum Institute of India.
Recombinant BCG (Bacillus Calmette-Guérin) is described as a benign bacterium originally developed as a live vaccine against tuberculosis.